Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK

被引：0
|
作者：
Modar Khalil
Hassan W Zafar
Victoria Quarshie
Fayyaz Ahmed
机构：
[1] Hull Royal Infirmary,Specialist Registrar in Neurology
[2] Hull Royal Infirmary,Specialist Headache Nurse
[3] Consultant Neurologist,undefined
[4] Hull Royal Infirmary,undefined
来源：
The Journal of Headache and Pain | 2014年 / 15卷
关键词：
Migraine; National Health Service; Chronic Migraine; Medication Overuse; Episodic Migraine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year
    I. Aicua-Rapun
    E. Martínez-Velasco
    A. Rojo
    A. Hernando
    M. Ruiz
    A. Carreres
    E. Porqueres
    S. Herrero
    F. Iglesias
    A. L. Guerrero
    The Journal of Headache and Pain, 2016, 17
  • [32] Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year
    Aicua-Rapun, I.
    Martinez-Velasco, E.
    Rojo, A.
    Hernando, A.
    Ruiz, M.
    Carreres, A.
    Porqueres, E.
    Herrero, S.
    Iglesias, F.
    Guerrero, A. L.
    JOURNAL OF HEADACHE AND PAIN, 2016, 17
  • [33] Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy
    Antonio Santoro
    Massimiliano Copetti
    Anna M. Miscio
    Maurizio A. Leone
    Andrea Fontana
    Neurological Sciences, 2020, 41 : 1809 - 1820
  • [34] Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy
    Santoro, Antonio
    Copetti, Massimiliano
    Miscio, Anna M.
    Leone, Maurizio A.
    Fontana, Andrea
    NEUROLOGICAL SCIENCES, 2020, 41 (07) : 1809 - 1820
  • [35] Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data
    Dodick, David W.
    Silberstein, Stephen D.
    Lipton, Richard B.
    DeGryse, Ronald E.
    Adams, Aubrey Manack
    Diener, Hans-Christoph
    CEPHALALGIA, 2019, 39 (08) : 945 - 956
  • [36] EARLY AND SUSTAINED EFFECT OF ONABOTULINUMTOXINA FOR CHRONIC MIGRAINE TREATMENT: ANALYSIS OF PREEMPT DATA
    Dodick, David W.
    Silberstein, Stephen D.
    Lipton, Richard B.
    DeGryse, Ronald E.
    Adams, Aubrey Manack
    Diener, Hans-Christoph
    TOXICON, 2018, 156 : S23 - S24
  • [37] Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes
    J. Talbot
    R. Stuckey
    L. Crawford
    S. Weatherby
    S. Mullin
    The Journal of Headache and Pain, 2021, 22
  • [38] Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes
    Talbot, J.
    Stuckey, R.
    Crawford, L.
    Weatherby, S.
    Mullin, S.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01)
  • [39] Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine
    Sarchielli, Paola
    Romoli, Michele
    Corbelli, Ilenia
    Bernetti, Laura
    Verzina, Angela
    Brahimi, Elona
    Eusebi, Paolo
    Caproni, Stefano
    Calabresi, Paolo
    FRONTIERS IN NEUROLOGY, 2017, 8
  • [40] OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients without medication overuse
    Diener, H. C.
    Dodick, D. W.
    DeGryse, R. E.
    Turkel, C. C.
    JOURNAL OF HEADACHE AND PAIN, 2013, 14
12345